Despite a rocky past with federal officials and an initial rejection in March from the FDA, Elon Musk’s brain-chip company Neuralink shared on Twitter that it has received FDA approval to launch its first in-human clinical study.
Thursday that it has received FDA approval to launch its first in-human clinical study.
“This is the result of incredible work by the Neuralink team in close collaboration with the FDA and represents an important first step that will one day allow our technology to help many people,” the company said. Neuralink has yet to open recruitment for the clinical trial but expects to announce additional information soon.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Elon Musk’s Neuralink gets FDA approval for human test of brain implantsNeuralink is developing a brain implant it hopes will help paralyzed people walk again and cure other neurological ailments.
Lire la suite »
Elon Musk's Neuralink gets FDA approval for study of brain implants in humansElon Musk's brain-implant company Neuralink on Thursday said it had received the U.S. Food and Drug Administration's (FDA) approval to launch its first-in-human clinical study.
Lire la suite »
The FDA will apparently let Elon Musk put a computer in a human’s brainRecruitment for Neuralink’s trial isn’t open yet.
Lire la suite »
FDA Approves Buprenorphine Injection for Opioid Use DisorderThe FDA has approved extended-release injection buprenorphine (Brixadi, Braeburn Inc) for the treatment of moderate to severe opioid use disorder.
Lire la suite »
TransCon PTH Nears US Approval for Hypoparathyroidism?Palopegteriparatide is a potential long-term therapy for adults with hypoparathyroidism, new findings suggest.
Lire la suite »
COVID-19 pill Paxlovid gets full FDA approval after over a year of emergency useThursday’s action means the drug has now been fully vetted by the U.S. government and can remain on the market indefinitely.
Lire la suite »